Cryonics and Cryopreservation: Preserving the Body and Brain for Future Revival Technologies

1. Introduction: A Bet, Not a Treatment

Cryonics is the practice of preserving a legally dead person at cryogenic temperature in the hope that future medicine might revive them. The proposal rests on a temporal wager: today’s terminal diseases may be curable tomorrow, so arresting biological decay — above all the brain’s synaptic architecture — purchases an option on capabilities that do not yet exist. No cryopreserved human has ever been revived, and no mammal has been revived after whole-body cryopreservation. Cryonics should therefore not be described as medicine. It is a speculative custody arrangement whose plausibility depends entirely on whether the two independent technologies it requires — reversible biostasis and future repair — will ever exist.

Two very different fields are routinely conflated under one word. Cryobiology is an established experimental discipline concerned with the effects of low temperature on cells, tissues, and organs; it has produced real clinical products (frozen embryos, vitrified oocytes, banked organs and blood components). Cryonics is an unvalidated application of some of that science to whole humans. Separating the two is the first requirement for any honest assessment, and the rest of this article follows that separation.

2. What Cryobiology Has Actually Demonstrated

2.1. Cells and Gametes: Established Clinical Practice

The clearest successes are cellular. Sperm, red blood cells, and embryos have been cryopreserved for decades, and oocyte vitrification is now routine in assisted reproduction, where ice-crystal-free solidification avoids the mechanical damage that slow freezing inflicts on the spindle apparatus. These are genuine victories of the field, but they concern isolated cells or very small tissue volumes with a high surface-to-volume ratio, uniform cryoprotectant penetration, and no circulatory system to perfuse.

Evidence level: established (for cells and small reproductive tissues).

2.2. Tissue and Organ Vitrification: Emerging

Vitrification — cooling a solution fast enough that it solidifies into a glass-like amorphous state without forming ice — is the strategy that made cryonics plausible in principle, because ice crystallisation is the principal source of structural damage. Gregory Fahy and colleagues showed that organs can be loaded with concentrated cryoprotective agents (CPAs) and vitrified, and demonstrated preservation of function in small structures such as rabbit kidney tissue. The difficulties are quantitative and severe: as volume increases, both heat removal and cryoprotectant distribution become progressively harder, and CPA concentrations high enough to prevent ice formation are chemically toxic, especially when the tissue is warm.

Evidence level: emerging — whole organ vitrification with functional recovery after transplantation is not an established clinical reality.

2.3. The Brain Preservation Result and What It Does and Does Not Show

The most frequently cited result for cryonics advocates is aldehyde-stabilised cryopreservation (ASC). McIntyre and Fahy perfuse-fixed rabbit and pig brains with a glutaraldehyde-based fixative, gradually perfused ethylene glycol to 65% w/v, vitrified the brains at -135 °C, rewarmed them, and removed the cryoprotectant. Electron microscopy and focused-ion-beam imaging showed that membranes, organelles, neurites, and synapses were preserved to a degree suitable for connectomic tracing. The technique was developed as a brain-banking method for neuroanatomy, and it is important to note the logical structure of the result: the brain was chemically fixed, which permanently abolishes physiological function. ASC demonstrates excellent structural preservation; it says nothing about the preservation of a viable, revivable organ.

Evidence level: established for structure; not evidence of viability.

2.4. Rewarming: The Nanowarming Advance

If uniform cooling is hard, uniform rewarming is harder: slow or uneven warming causes recrystallisation, cracks, and thermal-mechanical stress. A significant step was the development of nanowarming — dispersing silica-coated iron oxide nanoparticles through the cryoprotectant and exciting them with radiofrequency to heat from within. Manuchehrabadi and colleagues used this to rewarm vitrified cells and tissues at rates above 130 °C/min with viability equal to or better than conventional warming in samples of roughly 1 to 50 millilitres. This is a real, published advance with direct relevance to organ banking. It is also, at present, scaled to tens of millilitres, not to a 70-kilogram human body.

Evidence level: emerging (tissue scale; no organ-scale human application).

3. Why Scaling to a Whole Human Is a Different Problem

Cryonics advocates often argue that the difference between an organ and a person is «only» scale. Biologically, however, several failure modes become qualitatively worse, not merely harder, as size and complexity increase.

3.1. Ischemia and the Timing Problem

Cryonics conventionally begins only after legal death is declared. At normothermia, the brain tolerates complete ischemia for only a few minutes before irreversible injury; the interval between death and the start of effective perfusion is frequently tens of minutes to hours, and an autopsy declaration often entails a deliberate waiting period. Hypothermia and cardiopulmonary support can extend the tolerable interval somewhat, but this is precisely the interval during which the fine synaptic and molecular detail that the whole thesis depends on may be degrading. The practical quality of preservation is therefore limited at least as much by the pre-preservation logistics as by the cryobiology itself.

3.2. Cryoprotectant Toxicity and Perfusion Heterogeneity

Whole-body perfusion must deliver a vitrifiable cryoprotectant concentration to every tissue while the tissue is still warm enough for the chemistry to be toxic. Capillary density, the blood-brain barrier, and the sheer vascular distance make uniform loading of the brain difficult to verify. Even a vitrified brain is not a static object: without further processing, cryoprotectant must eventually be removed from every cell, a problem that ASC sidestepped by first fixing the tissue — which cryonics cannot do if viability is the goal.

3.3. Fracture, Devitrification, and Heat Transfer

Large glassy volumes accumulate thermal gradients that produce fracture on cooling and crystallisation (devitrification) on warming. Nanowarming offers a possible route through this, but extending radiofrequency uniformity and nanoparticle distribution to an entire human body, and then removing the nanoparticles, remains unsolved. There is no demonstrated method for rewarming a body-scale vitrified mass without cracking or phase change.

3.4. Structure Is Not Function

This is the central conceptual gap. Every impressive cryopreservation result cited in cryonics debates is a result about structure. Maintaining an intact connectome is not the same as maintaining the ion gradients, membrane potentials, protein folding states, mitochondrial function, and immune compatibility that a living, functioning brain requires. A conventionally frozen tissue that looks perfect ultrastructurally may be metabolically dead. Cryonics assumes that future technology could bridge this gap by repairing the damage; that assumption is the speculative core, not an established fact.

4. The Information-Theoretic and Identity Argument

The strongest argument for cryonics is not cryobiological but informational. If personal identity is encoded in the brain’s connectome and its molecular state, a claim can be made that preserving that information — by any means, including destructive fixation followed by future reconstruction — preserves the person. On this view, a future technology could in principle read the preserved structure and rebuild or emulate the mind, whether in biological tissue, on a computer, or in some other substrate.

This argument is coherent but rests on several unproven premises: (i) that identity and memory are fully determined by a particular physical state that current preservation captures; (ii) that the required resolution for capturing that state is known; and (iii) that subjective continuity or a sufficiently faithful reconstruction qualifies as survival. None of these is experimentally testable today. The argument also sits in tension with a related strategy, whole-brain emulation, which makes the same informational assumptions but proposes scanning a living brain rather than reviving a preserved one (see the companion article on brain emulation).

Evidence level: hypothesis to speculation. The information-theoretic premise is a philosophical position, not a scientific result, and both its defenders and its critics are currently unfalsifiable on the central question.

5. Practice, Cost, and Custody Risk

Cryonics providers (for example Alcor, the Cryonics Institute, KrioRus, and Tomorrow Bio) offer two options. Whole-body preservation seeks to retain the entire organism; neuropreservation keeps only the head or brain, betting explicitly on the reconstructability of the body or its replacement. Providers maintain standby teams, perfusion protocols, and long-term patient-care trusts, usually funded by life-insurance policies. Advertised costs have historically ranged from roughly $80,000 for neuropreservation to $200,000 or more for whole-body preservation, though these figures vary by provider and over time and should be treated as advertised pricing rather than established fact.

Two structural risks dominate the practice. The first is custody risk over century-long timescales: an organisation must remain solvent, competent, and supplied with liquid nitrogen across a period longer than most institutions survive. The 1979 failure of the Cryonics Society of California, in which several patients were found to have decomposed, remains the canonical illustration of this risk. The second is the unfalsifiability of the value proposition: because revival cannot be attempted until the required technology exists, no subscriber can verify the outcome within a conventional evidentiary horizon.

6. Application to Lifespan Extension

Cryonics extends nothing today. Its entire value proposition lies in a low-probability, high-payoff future in which both reversible biostasis and comprehensive repair exist. A rational framing assigns most of the probability mass to permanent non-revival, with a small residual chance of revival into an era capable of repairing both the original disease and the preservation damage. Under that framing cryonics is best understood as a call option on the entire longevity enterprise: inexpensive relative to its hypothetical payoff, and worthless if the underlying science stalls.

It is worth stating plainly what cryonics is not. It is not a treatment for the disease that killed the patient, and it does not slow aging. Unlike caloric restriction, senolytics, or organ replacement — interventions with measurable effects on biological age or survival in defined models — cryonics has no demonstrated mechanism of benefit and no outcome data. Its contribution to longevity science is indirect and real: pressure from the field has advanced interest in organ banking and vitrification, which have genuine transplant-medicine applications regardless of whether any patient ever wakes.

7. Limitations and Open Questions

• No revival precedent. Not a single mammal, let alone a human, has been revived after whole-body cryopreservation. The claim is extrapolated from cell- and tissue-scale results.
• Ischemia dominates the outcome. Preservation quality depends heavily on how quickly and how well perfusion begins, which is outside the subscriber’s control.
• Structure-function gap. Even perfect ultrastructure does not imply viability or the persistence of memory and identity.
• Untestability. The central claim cannot be evaluated with current methods, placing it outside normal scientific adjudication.
• Institutional durability. Multi-decade custody depends on organisational survival that cannot be guaranteed.
• Professional distance. Mainstream cryobiologists and professional societies generally distinguish organ-preservation research from cryonics and do not endorse it as a therapeutic or preservation method.

8. Future Directions

Organ banking. The most impactful near-term goal is not human preservation but extending the usable time window for transplantable organs. Nanowarming, improved CPA cocktails, and machine perfusion are advancing this directly, and success here would be a genuine medical achievement independent of cryonics.

Better pre-preservation logistics. Faster cooling, field-deployable perfusion, and pharmacological protection against ischemic injury could improve the starting condition of any preserved tissue. Advances here would benefit stroke and cardiac-arrest care as well.

Reversibility benchmarks in model systems. Progress is best tracked not by promotional claims but by peer-reviewed demonstrations of functional recovery in increasingly complex, vascularised tissues after vitrification and rewarming. Until an organ-scale reversal is published, the human-scale claim remains unsupported.

9. Conclusion

Cryonics is neither proven medicine nor mere quackery. It is a structured, unfalsifiable bet that future repair technologies will value preserved neural information — a bet whose scientific foundations come almost entirely from cryobiology, a field that has delivered real results for cells and small tissues and nothing for whole organisms. The honest summary is that structural preservation of brain tissue is demonstrable, viability preservation at organ scale is not, and revival of a person is speculative in the strict sense of the word. Those who subscribe should understand that they are purchasing a chance, not a cure, and that the chance is contingent on advances — and institutional continuity — that no one can presently promise.

Sources and Key Research Centers

1. Song A, Fahy GM. «Aldehyde-stabilized cryopreservation.» Cryobiology, 2015; 71(3): 448-458. DOI: 10.1016/j.cryobiol.2015.09.003 — Structural preservation of whole rabbit and pig brains used as a connectomics brain-banking method.
2. Fahy GM, Wowk B, Wu J, et al. «Cryopreservation of organs by vitrification: perspectives and recent advances.» Cryobiology, 2004; 48(2): 157-178. DOI: 10.1016/j.cryobiol.2004.02.002 — Foundational review of organ vitrification and its obstacles.
3. Manuchehrabadi N, Gao Z, Zhang J, et al. «Improved tissue cryopreservation using inductive heating of magnetic nanoparticles.» Science Translational Medicine, 2017; 9(379): eaah4586. DOI: 10.1126/scitranslmed.aah4586 — Nanowarming of cells and tissues at up to 80 mL scale.
4. Kuwayama M, Vajta G, Kato O, Leibo SP. «Highly efficient vitrification method for cryopreservation of human oocytes.» Reproductive BioMedicine Online, 2005; 11(3): 300-308. DOI: 10.1016/S1472-6483(10)60837-1 — Clinical vitrification of human oocytes.
5. Alcor Life Extension Foundation — Standby, perfusion, and long-term patient-care operations of a major cryonics provider.
6. Cryonics Institute — Provider founded by Robert Ettinger, author of «The Prospect of Immortality» (1964).
7. National Institute of Biomedical Imaging and Bioengineering (NIBIB) — Federal support for organ-banking, vitrification, and rewarming research with transplant applications.
8. PubMed: vitrification and organ cryopreservation — Peer-reviewed record of what cryobiology can and cannot yet preserve.